Indications
Prevention and treatment of influenza and acute respiratory viral infections in adults and children over 14 years of age.
$40.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: |
Prevention and treatment of influenza and acute respiratory viral infections in adults and children over 14 years of age.
The drug is administered intranasally by aerosol use of 1 dose (1 dose = 1 short press on the dispenser). At the first signs of the disease, Genferon ® Light is administered intranasally for 5 days, one dose (one tap on the dispenser) in each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alpha, the daily dose should not exceed 500,000 IU). In case of contact with a patient with acute respiratory viral infections and / or hypothermia, the drug is administered according to the indicated scheme 2 times a day for 5-7 days. If necessary, preventive courses are repeated. Instructions for using the spray:Remove the protective cap. Before using it for the first time, press the dispenser several times until a thin stream appears. Keep the bottle in an upright position when using it. Inject the drug by pressing the dispenser once into each nasal passage in turn. After use, close the dispenser with a protective cap.
Individual use is recommended to avoid the spread of infection.
Hypersensitivity to Interferon alfa-2b or other components of the drug.
Children under 14 years of age.
1 dose of the drug contains:
active ingredients: human recombinant Interferon alfa-2b * 50,000 IU, taurine 1 mg
. excipients: disodium edetate dihydrate, glycerol, dextran 40,000, polysorbate 80, sodium chloride, potassium chloride, sodium hydrophosphate dodecahydrate, potassium dihydrogen phosphate, peppermint oil, methyl parahydroxybenzoate, water for injection up to 0.1 ml.
* The composition of the substance “Interferon alfa-2b human recombinant (rfIFN-a2b), substance-solution” includes Interferon alfa-2b human recombinant (rfIFN-a2b) and auxiliary substances: sodium chloride, sodium acetate trihydrate, ice acetic acid, water for injection.
1 dose of the drug contains:
active ingredients: human recombinant Interferon alfa-2b * 50,000 IU, taurine 1 mg
. excipients: disodium edetate dihydrate, glycerol, dextran 40,000, polysorbate 80, sodium chloride, potassium chloride, sodium hydrophosphate dodecahydrate, potassium dihydrogen phosphate, peppermint oil, methyl parahydroxybenzoate, water for injection up to 0.1 ml.
* The composition of the substance “Interferon alfa-2b human recombinant (rfIFN-a2b), substance-solution” includes Interferon alfa-2b human recombinant (rfIFN-a2b) and auxiliary substances: sodium chloride, sodium acetate trihydrate, ice acetic acid, water for injection.
Genferon ® light contains recombinant human Interferon alfa-2b, produced by a strain of the bacterium Escherichia coli, into which the human Interferon alfa-2b gene has been genetically engineered. Interferon alfa-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects.
The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested primarily by an increase in cell-mediated responses of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved by activating CD8+ killer T cells, NK cells (natural killers), and enhancing differentiation.
B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as an increase in the expression of molecules of the main type I histocompatibility complex, which increases the probability of recognition of infected cells by immune system cells. Activation of white blood cells contained in all layers of the mucous membrane under the influence of interferon ensures their active
participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by immune system reactions enhanced under the influence of interferon.
Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulatory effect.
Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps preserve the biological activity of interferon, enhancing the therapeutic effect of the drug.
Pharmacokinetics
When applied intranasally, due to the high concentration in the focus of infection, a pronounced local antiviral and immunostimulating effect is achieved.
Systemic absorption of the drug is insignificant – the low bioavailability of drugs when administered intranasally is associated with the functioning of a special family of proteins from 25 proteins that make up the nasal mucosa and control the transport of all molecular and cellular objects that penetrate the mucosa.
At the same time, a certain amount of the drug enters the systemic bloodstream, due to which a systemic immunomodulatory effect is achieved.
Prevention and treatment of influenza and acute respiratory viral infections in adults and children over 14 years of age.
Hypersensitivity to Interferon alfa-2b or other components of the drug.
Children under 14 years of age.
Possible allergic reactions, spotting from the nose.
As a rule, these reactions are mild and do not require additional drug therapy.
Simultaneous use of intranasal vasoconstrictors is not recommended, as this contributes to additional drying of the nasal mucosa.
The drug is administered intranasally by aerosol use of 1 dose (1 dose = 1 short press on the dispenser). At the first signs of the disease, Genferon ® Light is administered intranasally for 5 days, one dose (one tap on the dispenser) in each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alpha, the daily dose should not exceed 500,000 IU). In case of contact with a patient with acute respiratory viral infections and / or hypothermia, the drug is administered according to the indicated scheme 2 times a day for 5-7 days. If necessary, preventive courses are repeated. Instructions for using the spray: Remove the protective cap. Before using it for the first time, press the dispenser several times until a thin stream appears. Keep the bottle in an upright position when using it. Inject the drug by pressing the dispenser once into each nasal passage in turn. After use, close the dispenser with a protective cap. Individual use is recommended to avoid the spread of infection.
No cases of overdose of Genferon® Light have been reported.
100 doses in a dark glass bottle, sealed with a dispenser with a protective cap. 1 bottle with instructions for use in a cardboard pack.
Store and transport in a dry place protected from light at a temperature of 2 to 8 °C. Keep out of reach of children.
life is 2 years.
Interferon alfa-2b, Taurine
nasal spray
Flu, SARS, Flu prevention
Reviews
There are no reviews yet